89Bio Inc (ETNB)

$14.85 +0.01 (0.07%)
Market Cap 2.20B
Revenue (ttm) 0.00
Net Income (ttm) -367.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 1,698,300
Avg Vol 4,685,878
Day's Range N/A - N/A
Shares Out 148.31M
Stochastic %K 71%
Beta 1.27
Analysts Sell
Price Target $31.07

Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 415 432 9270
Address:
655 Montgomery Street, Suite 1500, San Francisco, United States
Tdorsey1776
Tdorsey1776 Oct. 3 at 3:03 PM
$ETNB Has anyone received tender offer from Roche for ETNB shares?
1 · Reply
Power2k
Power2k Oct. 3 at 1:24 PM
$VKTX The 3.5B takeover deal between $RHHBY and $ETNB took almost 3 yrs to mature, the Viking deal may even take much longer (4-5 yrs) considering a much higher TAM of the Obesity space, and we're a 3Billion company already. BL and the board members are working their butts off talking with multiple potential suitors and due diligences are conveyed between both parities almost on a daily basis. So let's be patient as the team is trying their best to get the company and us shareholders the deal as best as possible.
2 · Reply
Power2k
Power2k Oct. 3 at 12:44 PM
$AKRO $ETNB "On January 27, 2025, Akero Therapeutics, Inc. reported positive clinical trial results from a Phase 2b clinical trial in patients with compensated cirrhosis (fibrosis stage F4) due to MASH, which contributed to heightened industry focus on the FGF21 class of therapeutics and the fibrosis stage F4 segment. Shortly thereafter, representatives of Parent conveyed that Akero Therapeutics, Inc.’s data were a positive indicator for the class and that Parent wished to assemble a cross-functional team to engage in diligence with the intent of exploring a potential collaboration with 89bio." Are those Parties terminated talks with 89bio are in talks with Akero now? Man, we can't be just a "positive indicator", we are a major player in the MASH field. $VKTX $RHHBY https://www.fiercebiotech.com/biotech/after-courting-14-pharmas-89bio-was-left-between-roche-and-hard-place-buyout-talks
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 8:24 AM
$ETNB: Unusual Options Activity Alerted PUT flow observed 5000x contracts at Strike price of $14 Exp on 11/21/2025 with Premium of $100K and showing BEARISH Sentiment
0 · Reply
warrants_Moon
warrants_Moon Oct. 1 at 6:36 PM
$AKRO $ETNB you guys might want to check out $VKTX
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 1 at 4:15 PM
$ETNB Bought another 5k yesterday ETNB @ $14.70 (paying .20 for the CVRs) So, Im betting $2K with the chance to make $60,000. $14.50 per share in cash at closing. In addition, 89bio's stockholders will receive a non-tradeable CVR to receive up to an aggregate of $6.00 per share in cash, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis. Each non-tradeable CVR will entitle its holders to receive the following contingent cash payments, conditioned upon the achievement of certain milestones, within specified time periods: $2.00 per share in cash, upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients (by March 31, 2030) $1.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $3.0 billion in any calendar year (by December 31, 2033) $2.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $4.0 billion in any calendar year (by December 31, 2035)
1 · Reply
BioRich
BioRich Oct. 1 at 1:22 PM
$ALT Morning Reality Check (The Dreaded Chart): If you have invested in $GUTS a month ago, you'd have a better return than 2 companies that got bought out ($MTSR and $ETNB) and a 60+% gain over $ALT. When I suggest that $ALT is dead and folks are better suited taking the tax loss and investing in $GUTS, I wasn't kidding. You would have made all of your money back, rather than pumping the next hopeful event. Reality is not your friend $ALT'ers. Listen, learn and act. Holding on to your bags for emotional and group therapy reasons isn't going to make you Rich. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI
0 · Reply
highnihilism
highnihilism Sep. 30 at 1:01 PM
$COHU Cohu: 21 trades, $14.7K vs $5.8K avg (2.54x). $11.9K calls / $2.8K puts. $MHK Mohawk Industries: 32 trades, $21.3K vs $331.5K avg (0.06x). $11.9K calls / $9.4K puts. $ETNB 89Bio: 566 trades, $382.1K vs $78.3K avg (4.88x). $11.9K calls / $370.2K puts. $EWH iShares MSCI Hong Kong ETF: 91 trades, $14.8K vs $62.1K avg (0.24x). $11.9K calls / $3K puts.
0 · Reply
OnlyFibs
OnlyFibs Sep. 29 at 9:30 PM
RECAP 9/29 Unusual Puts: $OXY Dec 43.5 P $ETNB Nov 14 P $VZ Mar 37 P
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 29 at 8:01 PM
RECAP 9/29 Unusual Puts: $OXY Dec 43.5 P $ETNB Nov 14 P $VZ Mar 37 P Live Breaking trading news www.openoutcrier.com
0 · Reply
Latest News on ETNB
3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 15 days ago

3 Potential Biotech Acquisition Targets

AZN INCY MLYS SNDX TVTX

89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Sep 19, 2025, 12:24 PM EDT - 15 days ago

89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Sep 18, 2025, 12:34 PM EDT - 16 days ago

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Roche to Buy 89bio for Up to $3.5 Billion

Sep 18, 2025, 1:29 AM EDT - 16 days ago

Roche to Buy 89bio for Up to $3.5 Billion

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Sep 18, 2025, 1:18 AM EDT - 16 days ago

Roche to acquire liver drug developer 89bio for up to $3.5 billion

89bio, Inc. Announces Agreement to be Acquired by Roche

Sep 18, 2025, 1:02 AM EDT - 16 days ago

89bio, Inc. Announces Agreement to be Acquired by Roche

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 9, 2025, 10:09 AM EDT - 25 days ago

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 4:05 PM EDT - 4 weeks ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:05 PM EDT - 4 weeks ago

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript

89bio to Participate in Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 5 weeks ago

89bio to Participate in Upcoming Investor Conferences

89bio: Promising As Pegozafermin Nears Phase 3 Readout

Aug 11, 2025, 8:22 AM EDT - 7 weeks ago

89bio: Promising As Pegozafermin Nears Phase 3 Readout

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 7, 2025, 4:05 PM EDT - 2 months ago

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 4 months ago

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

May 1, 2025, 4:05 PM EDT - 5 months ago

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

Apr 18, 2025, 4:46 AM EDT - 6 months ago

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

89bio to Participate in the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 7 months ago

89bio to Participate in the Leerink Partners Global Healthcare Conference

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 27, 2025, 4:05 PM EST - 7 months ago

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

89bio's Pegozafermin Is Now Gaining Momentum

Jan 30, 2025, 6:05 AM EST - 8 months ago

89bio's Pegozafermin Is Now Gaining Momentum

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 28, 2025, 10:31 PM EST - 8 months ago

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Jan 27, 2025, 4:12 PM EST - 8 months ago

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

Jan 13, 2025, 6:08 PM EST - 9 months ago

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Nov 15, 2024, 8:05 AM EST - 11 months ago

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2024, 11:58 PM EST - 11 months ago

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio to Participate in the UBS Global Healthcare Conference

Nov 5, 2024, 4:05 PM EST - 11 months ago

89bio to Participate in the UBS Global Healthcare Conference

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

Oct 15, 2024, 8:30 AM EDT - 1 year ago

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 4:05 PM EDT - 1 year ago

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

Sep 16, 2024, 4:05 PM EDT - 1 year ago

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 7, 2024, 1:59 PM EDT - 1 year ago

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio Appoints Francis Sarena as Chief Operating Officer

Aug 7, 2024, 8:00 AM EDT - 1 year ago

89bio Appoints Francis Sarena as Chief Operating Officer

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

Aug 5, 2024, 4:05 PM EDT - 1 year ago

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23, 2024, 6:32 AM EDT - 1 year ago

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

May 22, 2024, 4:05 PM EDT - 1 year ago

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

May 14, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:05 PM EDT - 1 year ago

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

89bio to Participate in the BofA Securities 2024 Health Care Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

89bio to Participate in the BofA Securities 2024 Health Care Conference

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

May 2, 2024, 4:05 PM EDT - 1 year ago

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Apr 17, 2024, 4:05 PM EDT - 1 year ago

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Mar 27, 2024, 8:00 AM EDT - 1 year ago

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

Mar 12, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 8, 2024, 4:05 PM EST - 1 year ago

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Leerink Partners Global Biopharma Conference

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Feb 29, 2024, 4:05 PM EST - 1 year ago

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 12, 2023, 7:30 AM EST - 1 year ago

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 7, 2023, 7:00 AM EST - 1 year ago

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio: Despite Peer Trial Setback, Potential Remains In NASH

Dec 6, 2023, 6:59 PM EST - 1 year ago

89bio: Despite Peer Trial Setback, Potential Remains In NASH

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

Dec 4, 2023, 7:00 AM EST - 1 year ago

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

Nov 27, 2023, 8:00 AM EST - 2 years ago

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

Tdorsey1776
Tdorsey1776 Oct. 3 at 3:03 PM
$ETNB Has anyone received tender offer from Roche for ETNB shares?
1 · Reply
Power2k
Power2k Oct. 3 at 1:24 PM
$VKTX The 3.5B takeover deal between $RHHBY and $ETNB took almost 3 yrs to mature, the Viking deal may even take much longer (4-5 yrs) considering a much higher TAM of the Obesity space, and we're a 3Billion company already. BL and the board members are working their butts off talking with multiple potential suitors and due diligences are conveyed between both parities almost on a daily basis. So let's be patient as the team is trying their best to get the company and us shareholders the deal as best as possible.
2 · Reply
Power2k
Power2k Oct. 3 at 12:44 PM
$AKRO $ETNB "On January 27, 2025, Akero Therapeutics, Inc. reported positive clinical trial results from a Phase 2b clinical trial in patients with compensated cirrhosis (fibrosis stage F4) due to MASH, which contributed to heightened industry focus on the FGF21 class of therapeutics and the fibrosis stage F4 segment. Shortly thereafter, representatives of Parent conveyed that Akero Therapeutics, Inc.’s data were a positive indicator for the class and that Parent wished to assemble a cross-functional team to engage in diligence with the intent of exploring a potential collaboration with 89bio." Are those Parties terminated talks with 89bio are in talks with Akero now? Man, we can't be just a "positive indicator", we are a major player in the MASH field. $VKTX $RHHBY https://www.fiercebiotech.com/biotech/after-courting-14-pharmas-89bio-was-left-between-roche-and-hard-place-buyout-talks
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 8:24 AM
$ETNB: Unusual Options Activity Alerted PUT flow observed 5000x contracts at Strike price of $14 Exp on 11/21/2025 with Premium of $100K and showing BEARISH Sentiment
0 · Reply
warrants_Moon
warrants_Moon Oct. 1 at 6:36 PM
$AKRO $ETNB you guys might want to check out $VKTX
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 1 at 4:15 PM
$ETNB Bought another 5k yesterday ETNB @ $14.70 (paying .20 for the CVRs) So, Im betting $2K with the chance to make $60,000. $14.50 per share in cash at closing. In addition, 89bio's stockholders will receive a non-tradeable CVR to receive up to an aggregate of $6.00 per share in cash, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis. Each non-tradeable CVR will entitle its holders to receive the following contingent cash payments, conditioned upon the achievement of certain milestones, within specified time periods: $2.00 per share in cash, upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients (by March 31, 2030) $1.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $3.0 billion in any calendar year (by December 31, 2033) $2.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $4.0 billion in any calendar year (by December 31, 2035)
1 · Reply
BioRich
BioRich Oct. 1 at 1:22 PM
$ALT Morning Reality Check (The Dreaded Chart): If you have invested in $GUTS a month ago, you'd have a better return than 2 companies that got bought out ($MTSR and $ETNB) and a 60+% gain over $ALT. When I suggest that $ALT is dead and folks are better suited taking the tax loss and investing in $GUTS, I wasn't kidding. You would have made all of your money back, rather than pumping the next hopeful event. Reality is not your friend $ALT'ers. Listen, learn and act. Holding on to your bags for emotional and group therapy reasons isn't going to make you Rich. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI
0 · Reply
highnihilism
highnihilism Sep. 30 at 1:01 PM
$COHU Cohu: 21 trades, $14.7K vs $5.8K avg (2.54x). $11.9K calls / $2.8K puts. $MHK Mohawk Industries: 32 trades, $21.3K vs $331.5K avg (0.06x). $11.9K calls / $9.4K puts. $ETNB 89Bio: 566 trades, $382.1K vs $78.3K avg (4.88x). $11.9K calls / $370.2K puts. $EWH iShares MSCI Hong Kong ETF: 91 trades, $14.8K vs $62.1K avg (0.24x). $11.9K calls / $3K puts.
0 · Reply
OnlyFibs
OnlyFibs Sep. 29 at 9:30 PM
RECAP 9/29 Unusual Puts: $OXY Dec 43.5 P $ETNB Nov 14 P $VZ Mar 37 P
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 29 at 8:01 PM
RECAP 9/29 Unusual Puts: $OXY Dec 43.5 P $ETNB Nov 14 P $VZ Mar 37 P Live Breaking trading news www.openoutcrier.com
0 · Reply
CalculatedSwing
CalculatedSwing Sep. 27 at 9:36 PM
$GLMD $GLMD 🚀 Don’t sleep on this NASH play! Holding strong for Q4 catalysts: Aramchol Phase 3 data drop (AASLD or Nov earnings) + new patent to 2039 w/ Rezdiffra combo potential. $50B NASH market awaits. Analysts scream BUY ($6.50–$17 targets). Tariffs? Pre-commercial, so minimal hit. MACD flipped bullish, dip to $1.20 = buy zone. 💪 Join the ride w/ $GILD $MRTX $VKTX $ETNB #biotech
1 · Reply
Tdorsey1776
Tdorsey1776 Sep. 26 at 2:44 PM
$ETNB B 5k ETNB @ $14.70 (paying .20 for the CVRs) $14.50 per share in cash at closing, representing an aggregate payment of $2.4 billion. In addition, 89bio's stockholders will receive a non-tradeable CVR to receive up to an aggregate of $6.00 per share in cash, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis. Each non-tradeable CVR will entitle its holders to receive the following contingent cash payments, conditioned upon the achievement of certain milestones, within specified time periods: $2.00 per share in cash, upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients (by March 31, 2030) $1.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $3.0 billion in any calendar year (by December 31, 2033) $2.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $4.0 billion in any calendar year (by December 31, 2035)
1 · Reply
namv
namv Sep. 25 at 9:59 PM
$PFE $ROCM $ETNB $MTSR everyone getting bought up in the weight loss and mash sector… don’t get left behind get into $ALT before it’s too late
0 · Reply
Letsinvest2024
Letsinvest2024 Sep. 24 at 8:06 PM
$ETNB how much does the stock worth after the buyout offer? $18 ?
1 · Reply
Theflash88
Theflash88 Sep. 24 at 7:25 PM
$ETNB $MTSR $VKTX Way too low! $100 minimum. $140 likely.. imo
0 · Reply
Orkay
Orkay Sep. 24 at 5:10 PM
$VKTX I will not be surprised VKTX gets BO for $70+. They have made good progress with GLP1 and MASH. Very cheap valuation. in last 2 weeks, $ETNB and $MTSR were taken. Not many quality companies left to snatch
2 · Reply
GPTInsights
GPTInsights Sep. 24 at 1:54 PM
$VKTX Head scratcher how the market is capitulating here at $2.8 billion market cap when both $ETNB and $MTSR sold for more (more than double in MTSR case). Viking having the equivalent of both pipelines combined but better with MASH VK2809 and VK2753 likely BIC GLP/GIP SQ and oral assets both in phase 3 with 800 million cash to commercialize both.
2 · Reply
vu_jade
vu_jade Sep. 23 at 9:38 PM
$VKTX Take emotion out of it: $ETNB $3.2 billion $MTSR $7.3 Billion They can play all the games they want .. that’s our range. Viking equivalents $30 & $70 #Skol
2 · Reply
BioRich
BioRich Sep. 23 at 5:35 PM
$ALT Friendly reminder, it's been about 6 months since $ALT "apparently" turned down offers from "up to" 3 potential suitors. 6 months, the approximate time many think a deal would take. The approximate time it likely too for $ETNB and $MTSR to get their deals done. Simple logic would lend to $ALT turning down an offer (or offers) that were then spent to acquire ETNB and MTSR. I've been warning about $ALT's greed being a hindrance to their success, and this appears to be another example of this. SP was around ~$6/share at that point. How much do you think $ALT turned down and how many wish they would have taken it? https://seekingalpha.com/news/4420826-altimmune-stock-rises-buyout-rd-news Cheers!
1 · Reply
Al0
Al0 Sep. 23 at 7:25 AM
$ETNB T212 😎
0 · Reply
DG20
DG20 Sep. 23 at 3:48 AM
$ETNB $MTSR $PFE $RHHBY $VKTX AI loves a few of the Viking posters 🤔
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 23 at 2:44 AM
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ $VKTX $PFE $MTSR $ETNB $RHHBY https://stocktwits.com/news/equity/markets/viking-therapeutics-stock-boost-pfizer-metsera-deal-btig-retail-slams-rivals-inferior-pipelines/chDhieAR3P5
0 · Reply